The company's recent acquisition of KITE Pharma came at the perfect moment with KITE being granted a key drug approval by the FDA.
Gilead's recent cost cutting efforts and R&D focus are to further push growth prospect and boost overall FY guidance.
Generic competition will continue to weigh, however, and limit some blockbuster drug expansion.
I'm starting Gilead with a $90 PT for an extended post-earnings move.
A S/L at $75 around recent area is advised.